ALLR ALLARITY THERAPEUTICS INC revenue, earnings and financials
For the quarter ended June 30, 2026, ALLARITY THERAPEUTICS INC reported revenue of $0, net income of −$3.41M and diluted EPS of n/a; for the fiscal year ended December 2025 revenue was $320K.
ALLR annual revenue and earnings
- Fiscal year ended Dec 2025: revenue $320K, gross profit n/a, operating income −$12.6M, net income −$11.2M (margin -3509.7%), EPS n/a
- Fiscal year ended Dec 2024: revenue $0, gross profit n/a, operating income −$27.2M, net income −$24.5M (margin n/a), EPS n/a
- Fiscal year ended Dec 2023: revenue n/a, gross profit n/a, operating income −$17.1M, net income −$11.9M (margin n/a), EPS −$10.26
- Fiscal year ended Dec 2022: revenue n/a, gross profit −$2.27M, operating income −$34.5M, net income −$16.1M (margin n/a), EPS −$3093.42
- Fiscal year ended Dec 2021: revenue n/a, gross profit n/a, operating income −$26.6M, net income −$26.6M (margin n/a), EPS −$4.19
ALLR quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue $0, net income −$3.41M, EPS n/a
- Quarter ended Mar 31, 2026: revenue $25.0K, net income −$2.75M, EPS n/a
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income −$3.37M, EPS n/a
- Quarter ended Sep 30, 2025: revenue n/a, net income −$2.81M, EPS n/a
- Quarter ended Jun 30, 2025: revenue $0, net income −$2.32M, EPS n/a
- Quarter ended Mar 31, 2025: revenue $0, net income −$2.73M, EPS n/a
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$7.45M, EPS n/a
- Quarter ended Sep 30, 2024: revenue n/a, net income −$11.6M, EPS n/a
- Quarter ended Jun 30, 2024: revenue n/a, net income −$1.63M, EPS −$0.11
- Quarter ended Mar 31, 2024: revenue n/a, net income −$3.84M, EPS −$22.14
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$1.72M, EPS $6873.36
- Quarter ended Sep 30, 2023: revenue n/a, net income −$4.45M, EPS −$2.03
- Quarter ended Jun 30, 2023: revenue n/a, net income −$2.38M, EPS −$525.53
- Quarter ended Mar 31, 2023: revenue n/a, net income −$3.35M, EPS −$6356.06
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$2.84M, EPS −$2085.59
- Quarter ended Sep 30, 2022: revenue n/a, net income −$5.04M, EPS −$934.29
- Quarter ended Jun 30, 2022: revenue n/a, net income −$5.10M, EPS −$53.90
- Quarter ended Mar 31, 2022: revenue n/a, net income −$3.08M, EPS −$19.64
- Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$16.8M, EPS n/a
- Quarter ended Sep 30, 2021: revenue n/a, net income −$1.35M, EPS −$0.17
ALLR cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$14.8M, share buybacks $3.19M
- Fiscal year ended Dec 2024: operating cash flow −$17.4M, share buybacks $0
- Fiscal year ended Dec 2023: operating cash flow −$12.7M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$16.8M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$14.9M, share buybacks n/a
ALLR balance sheet
- Jun 30, 2026: cash $17.0M, total assets $32.1M, total liabilities $28.6M, shareholders' equity $3.54M
- Mar 31, 2026: cash $19.8M, total assets $34.9M, total liabilities $28.0M, shareholders' equity $6.92M
- Dec 31, 2025: cash $14.7M, total assets $18.3M, total liabilities $8.43M, shareholders' equity $9.83M
- Sep 30, 2025: cash $16.9M, total assets $20.8M, total liabilities $8.79M, shareholders' equity $12.0M
- Jun 30, 2025: cash $17.8M, total assets $21.2M, total liabilities $9.04M, shareholders' equity $12.2M
- Mar 31, 2025: cash $25.2M, total assets $29.7M, total liabilities $11.1M, shareholders' equity $18.7M
- Dec 31, 2024: cash $19.5M, total assets $22.7M, total liabilities $10.8M, shareholders' equity $11.8M
- Sep 30, 2024: cash n/a, total assets $20.4M, total liabilities $7.41M, shareholders' equity $13.0M
What is ALLR's revenue?
ALLARITY THERAPEUTICS INC reported $320K of revenue for the fiscal year ended December 2025.
Is ALLR profitable?
No. ALLARITY THERAPEUTICS INC lost $12.3M over the last four quarters.